Micron Technology, Inc. (MU)’s EVP – Technology Development Scott Deboer Sold 14,750 Shares; Cesca Therapeutics (KOOL) Shorts Up By 70.33%

Recently, the EVP – Technology Development of Micron Technology Inc, Mr. Scott Deboer, sold amount of shares – 14,750, amounting to $638,380 U.S Dollars, based on $43.3 per every share. Scott now owns 120,104 shares accounting for 0.01% of the Company’s market cap

Cesca Therapeutics Incorporated (NASDAQ:KOOL) had an increase of 70.33% in short interest. KOOL’s SI was 319,200 shares in February as released by FINRA. Its up 70.33% from 187,400 shares previously. With 198,400 avg volume, 2 days are for Cesca Therapeutics Incorporated (NASDAQ:KOOL)’s short sellers to cover KOOL’s short positions. The SI to Cesca Therapeutics Incorporated’s float is 19.19%. The stock decreased 3.75% or $0.1 during the last trading session, reaching $2.57. About 68,347 shares traded. Cesca Therapeutics Inc. (NASDAQ:KOOL) has declined 16.34% since February 10, 2017 and is downtrending. It has underperformed by 33.04% the S&P500.

The stock increased 1.02% or $0.41 during the last trading session, reaching $40.41. About 65.19 million shares traded or 56.95% up from the average. Micron Technology, Inc. (NASDAQ:MU) has risen 176.27% since February 10, 2017 and is uptrending. It has outperformed by 159.57% the S&P500.

Micron Technology, Inc. provides semiconductor systems worldwide. The company has market cap of $46.73 billion. The firm operates through four divisions: Compute and Networking Business Unit, Storage Business Unit, Mobile Business Unit, and Embedded Business Unit. It has a 6.32 P/E ratio. It offers DDR3 and DDR4 DRAM products for computers, servers, networking devices, communications equipment, consumer electronics, automotive, and industrial applications; lower power DRAM products for smartphones, tablets, automotive, laptop computers, and other mobile consumer device applications; DDR2 DRAM and DDR DRAM, GDDR5 and GDDR5X DRAM, SDRAM, and RLDRAM products for networking devices, servers, consumer electronics, communications equipment, computer peripherals, and automotive and industrial applications, as well as for computer memory upgrades; and hybrid memory cube semiconductor memory devices.

Among 42 analysts covering Micron Technology Inc. (NASDAQ:MU), 36 have Buy rating, 0 Sell and 6 Hold. Therefore 86% are positive. Micron Technology Inc. has $85 highest and $8 lowest target. $40.80’s average target is 0.97% above currents $40.41 stock price. Micron Technology Inc. had 214 analyst reports since July 29, 2015 according to SRatingsIntel. The company was upgraded on Wednesday, December 7 by Standpoint Research. The stock of Micron Technology, Inc. (NASDAQ:MU) has “Neutral” rating given on Thursday, August 20 by Robert W. Baird. The firm has “Neutral” rating by Goldman Sachs given on Thursday, March 31. Rosenblatt maintained Micron Technology, Inc. (NASDAQ:MU) on Tuesday, September 26 with “Buy” rating. The stock has “Outperform” rating by Macquarie Research on Tuesday, February 16. Goldman Sachs maintained the shares of MU in report on Wednesday, February 7 with “Buy” rating. The firm has “Market Perform” rating given on Monday, August 17 by Wells Fargo. The firm has “Hold” rating given on Thursday, July 27 by BMO Capital Markets. The company was maintained on Monday, December 18 by Rosenblatt. The stock of Micron Technology, Inc. (NASDAQ:MU) earned “Neutral” rating by Susquehanna on Friday, March 18.

Since August 16, 2017, it had 0 insider buys, and 13 selling transactions for $12.73 million activity. 25,000 shares were sold by Mondry Lawrence N, worth $765,485. On Thursday, October 19 the insider Deboer Scott J sold $1.26M. The insider BAILEY ROBERT L sold 3,000 shares worth $128,197. ARNZEN APRIL S also sold $10,507 worth of Micron Technology, Inc. (NASDAQ:MU) on Friday, September 1. Thorsen Steven L. JR also sold $4.53M worth of Micron Technology, Inc. (NASDAQ:MU) on Friday, September 29. Poppen Joel L had sold 80,000 shares worth $3.09M.

Investors sentiment increased to 1.37 in Q3 2017. Its up 0.29, from 1.08 in 2017Q2. It improved, as 52 investors sold Micron Technology, Inc. shares while 205 reduced holdings. 114 funds opened positions while 237 raised stakes. 886.67 million shares or 6.47% more from 832.79 million shares in 2017Q2 were reported. Invesco Limited owns 0.18% invested in Micron Technology, Inc. (NASDAQ:MU) for 12.27M shares. Whale Rock Cap Ltd Liability Co has 1.27% invested in Micron Technology, Inc. (NASDAQ:MU). Panagora Asset Management invested in 0.01% or 40,570 shares. Redwood Cap Mgmt Limited reported 250,000 shares. Moody Bank & Trust Tru Division has invested 0.02% of its portfolio in Micron Technology, Inc. (NASDAQ:MU). Us Savings Bank De holds 0% of its portfolio in Micron Technology, Inc. (NASDAQ:MU) for 37,963 shares. Cantab Capital Prtn Llp holds 29,949 shares. Oppenheimer Asset Management Inc invested in 308 shares. Fred Alger Management Inc reported 3.03M shares. Lincoln National Corp reported 6,556 shares stake. Northwest Invest Counselors Limited Com invested in 4,686 shares or 0.08% of the stock. Amica Retiree Medical holds 0.18% or 5,664 shares in its portfolio. Daiwa Sb Ltd reported 90 shares or 0% of all its holdings. San Francisco Sentry (Ca) reported 0% stake. Kepos Lp stated it has 0.12% of its portfolio in Micron Technology, Inc. (NASDAQ:MU).

Cesca Therapeutics Inc. focuses on the research, development, and commercialization of autologous cell therapeutics for use in regenerative medicine in the United States and internationally. The company has market cap of $27.94 million. The firm develops and makes automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. It currently has negative earnings. The Company’s products include SurgWerks system, a proprietary system comprised of the SurgWerks processing platform, including devices and analytics, and indication-specific SurgWerks procedure kits for use in regenerative stem cell therapy at the point of care for vascular and orthopedic diseases; CellWerks system, a proprietary cell processing system with associated analytics for intra-laboratory preparation of adult stem cells from bone marrow or blood; and AutoXpress system, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood.